NASDAQ:OPGN OpGen (OPGN) Stock Price, News & Analysis $3.06 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.01▼$3.0650-Day Range$2.36▼$3.8652-Week Range$1.65▼$38.40Volume4,991 shsAverage Volume11,545 shsMarket Capitalization$4.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get OpGen alerts: Email Address Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About OpGen Stock (NASDAQ:OPGN)OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Read More OPGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPGN Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comOpGen (NASDAQ:OPGN) Receives New Coverage from Analysts at StockNews.comJuly 8, 2024 | investorplace.comOPGN Stock Earnings: OpGen Reported Results for Q1 2024July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 5, 2024 | investorplace.comOPGN Stock Earnings: OpGen Meets Revenue for Q4 2023May 25, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 24, 2024 | globenewswire.comOpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMay 16, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Announced 1-for-10 Reverse Stock SplitMay 16, 2024 | globenewswire.comOpGen Announced 1-for-10 Reverse Stock SplitJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 4, 2024 | uk.finance.yahoo.comOpGen, Inc. (OPGN) stock price, news, quote & history – Yahoo FinanceApril 30, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Provides Update on Business Operations and Strategic OpportunitiesApril 29, 2024 | globenewswire.comOpGen Provides Update on Business Operations and Strategic OpportunitiesApril 27, 2024 | investing.comOpGen CEO David Lazar buys additional shares worth $150kApril 26, 2024 | finanznachrichten.deOpGen, Inc.: OpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 23, 2024 | globenewswire.comOpGen Receives Nasdaq Notice Regarding Delayed Form 10-KApril 22, 2024 | finance.yahoo.comOpGen, Inc. (OPGN)March 28, 2024 | msn.comShares Rip In Reaction To Activist Investor Becoming CEOMarch 27, 2024 | msn.comU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.08%See More Headlines Receive OPGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/08/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:OPGN CUSIPN/A CIK1293818 Webwww.opgen.com Phone(240) 813-1260Fax301-869-9684Employees85Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,670,000.00 Net Margins-997.34% Pretax Margin-955.79% Return on Equity-1,827.76% Return on Assets-188.39% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$3.42 million Price / Sales1.21 Cash FlowN/A Price / Cash FlowN/A Book Value($11.55) per share Price / Book-0.26Miscellaneous Outstanding Shares1,350,000Free Float758,000Market Cap$4.13 million OptionableNot Optionable Beta-0.65 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Oliver Schacht Ph.D. (Age 53)Executive VP of Corporate Development Comp: $408kMr. David Elliot Lazar (Age 33)CEO & Chairman Key CompetitorsPsychemedicsNASDAQ:PMDBioNexus Gene LabNASDAQ:BGLCAclarionNASDAQ:ACONDermTechNASDAQ:DMTKFresh2 GroupNASDAQ:FRESView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 331,890 shares on 5/2/2024Ownership: 2.630%View All Institutional Transactions OPGN Stock Analysis - Frequently Asked Questions How have OPGN shares performed this year? OpGen's stock was trading at $4.20 on January 1st, 2024. Since then, OPGN shares have decreased by 27.1% and is now trading at $3.06. View the best growth stocks for 2024 here. How were OpGen's earnings last quarter? OpGen, Inc. (NASDAQ:OPGN) announced its earnings results on Monday, July, 8th. The medical research company reported $0.21 earnings per share (EPS) for the quarter. The medical research company had revenue of $0.17 million for the quarter. OpGen had a negative trailing twelve-month return on equity of 1,827.76% and a negative net margin of 997.34%. When did OpGen's stock split? OpGen's stock reverse split before market open on Monday, May 20th 2024. The 1-10 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did OpGen IPO? OpGen (OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager. How do I buy shares of OpGen? Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of OpGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that OpGen investors own include Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Energy Transfer (ET), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV) and SCYNEXIS (SCYX). This page (NASDAQ:OPGN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OpGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OpGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
